儿童非重型再生障碍性贫血伴染色体异常的临床特征与预后分析
该研究回顾性分析2001至2014年304例成功进行核型分析的儿童非重型再生障碍性贫血(NSAA)病例。染色体异常发生率为9.2%,伴染色体异常患儿治疗反应与无异常者相似,但疾病进展率及进展为骨髓增生异常综合征(MDS)或急性髓系白血病(AML)的风险显著更高,预后更差。
要点
- 儿童NSAA染色体异常发生率为9.2%,常见类型包括8三体、7号染色体异常等。
- 伴染色体异常患儿治疗反应、摆脱输血率及5年生存率与无异常者无显著差异。
- 伴染色体异常患儿疾病进展率及进展为MDS或AML的风险显著高于无异常者。
核心结论
- 儿童NSAA染色体异常发生率为9.2%,伴异常者临床特征和治疗反应相似,但预后更差,进展为MDS或AML风险更高。
研究设计与样本
- 回顾性分析2001至2014年304例成功进行核型分析的儿童NSAA病例,采用χ2检验分析治疗反应和输血情况,Kaplan-Meier法估计累积生存率。
主要发现
- 28例(9.2%)存在染色体异常,其中8三体7例(25.0%),7号染色体异常5例(17.9%),其他类型16例(57.1%)。
- 伴与不伴染色体异常患儿治疗反应率分别为40.9%(9/22)和58.6%(119/203),差异无统计学意义(χ2=2.539,P=0.111)。
- 伴与不伴染色体异常患儿摆脱输血率分别为54.5%(6/11)和65.0%(39/60),差异无统计学意义(χ2=6.455,P=0.086)。
- 伴与不伴染色体异常患儿5年无进展生存率分别为49.2%和70.8%,差异无统计学意义(χ2=0.849,P=0.357);5年累积生存率分别为79.1%和92.8%,差异无统计学意义(χ2=0.330,P=0.556)。
- 伴与不伴染色体异常患儿疾病进展率分别为41.7%(10/24)和22.3%(48/215),差异有统计学意义(χ2=4.394,P=0.045);MDS或AML发生率分别为20.8%(5/24)和0.9%(2/215),差异有统计学意义(χ2=30.082,P=0.000);5年MDS或AML累积发生率分别为33.4%和0.8%,差异有统计学意义(χ2=17.798,P=0.000)。
临床怎么用
- 对儿童NSAA应进行核型分析以识别染色体异常,伴异常者需加强监测,警惕向MDS或AML进展。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To analyze the clinical characteristics and prognosis of non-severe aplastic anemia (NSAA) with chromosomal abnormalities in children. Method: A retrospective analysis of 304 cases with NSAA with successful karyotyping from 2001 to 2014 in the Institute of Hematology & Blood Disease Hospital was carried out. The treatment response, condition of blood transfusion were analyzed using χ2 test, the cumulative survival was estimated by the Kaplan-Meier method. Result: Out of 304 patients, 28 patients had chromosomal abnormalities with trisomy 8 (7 cases, 25.0%), abnormalities in chromosome 7 (5 cases, 17.9%), and other types (16 cases, 57.1%). There were no significant differences in the treatment response(40.9% (9/22)vs. 58.6%(119/203), χ2=2.539, P=0.111), the rate of getting rid of blood transfusion(54.5%(6/11) vs. 65.0%(39/60), χ2=6.455, P=0.086), five-year progression-free survival (49.2% vs.70.8%, χ2=0.849, P=0.357), and five-year cumulative survival (79.1% vs. 92.8%, χ2=0.330, P=0.556) between the patients with or without chromosomal abnormalities. There were significant differences in the rate of disease progression(41.7%(10/24) vs. 22.3%(48/215), χ2=4.394, P=0.045), the incidence of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) (20.8%(5/24)vs. 0.9%(2/215), χ2=30.082, P=0.000)and the five-year cumulative incidence of MDS or AML(33.4% vs. 0.8%, χ2=17.798, P=0.000)between children with and without chromosomal abnormalities. Conclusion: The incidence of chromosomal abnormalities in children with NSAA is 9.2%. The clinical features and treatment response are similar, but children with chromosomal abnormalities have a poorer prognosis, and have higher risk of progressing to MDS or AML.
引用
- Zhu S, An WB, Wan Y, et al. [Analysis of clinical characteristics and prognosis of non-severe aplastic anemia children with chromosomal abnormalities]. Zhonghua Er Ke Za Zhi. 2016. PMID: 27806787. doi:10.3760/cma.j.issn.0578-1310.2016.11.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。